Avid Bioservices Inc (CDMO)

[freethemice]

Here again is my table for phase 3 pancreatic cancer trials. This is a really hard nut to crack. If Bavi can make
headway here it will be very exciting. Note that in this historical context the numbers from the Threshold
phase IIb trial just announced are nothing to get excited about, and statistically the survival was not significant,
but the PFS was (p=0.005). PFS was the primary endpoint, but was not independently verified.
"The primary efficacy analysis was performed based upon 149 investigator-assessed PFS events and,
per protocol, pooled data from the two gemcitabine plus TH-302 dose groups in comparison to gemcitabine alone."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77501263